Enalapril: Synthesis and properties

Abstract

Enalapril was originally synthesized by Merck Sharp and Dohme and is an angiotensin converting enzyme inhibitor. Thus, enalapril is used in the treatment of mild to severe hypertension. Enalapril is chemically (S)-1-[N-[1-(et-hoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-prolin and although the first synthesis was published in 1980, it can be obtained using different synthetic pathways. This paper describes the synthesis as well as the properties and stability of enalapril.

Enalapril spada u Inhibitors angiotenzin-konvertujućeg-enzima (ACE) i predstavlja drugu generaciju takvih lekova. Prva sinteza enalaprila je razvijena u istraživačkim laboratorijama Merck Sharp & Dohme. U radu su prikazani načini dobijanja enalaprila, odnosno enalapril maleata koji se mogu naći u literaturi. Takođe je razmatrana i stabilnost enalaprila kao i način njegove degradacije.